

# Eva Bugallo Blanco

Research Scientist Immunology, UK

✉ evabugallo@gmail.com

☎ (+44) 7561491090

🌐 bugalloeva

🌐 https://evabugallo.com

## SUMMARY

Innovative and results-driven scientist with over 6 years of experience in oncology biologics. My expertise spans from antibody discovery to in vivo efficacy assessment of gene cell therapy products for oncology and autoimmune disease. Proven track record in leading multidisciplinary projects and managing external collaborations to drive novel biologics from concept to clinical trials. Passionate about leveraging AI and data-driven models to transform therapeutic design and accelerate drug discovery.

## EXPERIENCE

### Quell Therapeutics

Scientist, R&D

Feb 2024 - Present, London, UK

- Responsible for assessing the MoA of Tregs in different diseases.
- Leading a team in executing cell-based assays for candidate discovery and selection across multiple therapeutic platforms.
- Designed multi-colour FACs panel and cell-based assays in alignment with project timelines and milestones.
- Collaborating with cross-functional teams (Vector, PD, AD) to drive data integrity and meet project goals.
- Adaptable, accountable, and a solution-focused mindset.

### King's College London

Doctoral student

Oct 2019 - Mar 2024, London, UK

- Developed a novel non-invasive quantitation method for CAR T cells in preclinical models, presented at ISCT, EMIM and EACR.
- Optimised production and characterisation of traceable CAR T cells (in vitro & in vivo).
- Coordinate collaborative research with QMUL and ICR teams to drive scientific innovation in CAR T cell research.
- Established the hallmarks of severe COVID-19, Nature publication.

### UCL Institute of Child Health

Research Assistant

Jan 2018 - Sep 2019, London, UK

- Antibody discovery for the creation of next-generation therapeutics.
- Designed, produced and characterised novel CAR T cells, with a focus of increasing safety.
- 10x scRNAseq from tumour samples in collaboration with Sanger Institute.

## EDUCATION

### Ph.D. Immunotherapy and molecular imaging

King's College London

Oct 2019 - Mar 2024, London, UK

### MRes in Molecular and Cellular Biosciences

Imperial College London

Oct 2016 - Oct 2027, London, UK

### BSc in Biotechnology

University of Salamanca, University of Melbourne

Sep 2012 - Jun 2016, Spain & Australia

## KEY ACHIEVEMENTS

- ✓ **Candidate selection for clinical-phase therapeutics**  
Design, execution and analysis of functional assays successfully meeting milestones in collaboration with AstraZeneca.
- ☆ **Innovative with a troubleshooting attitude**  
Pioneered a novel mathematical approach to non-invasively quantify CAR T cell infiltration.
- \* **Thrive in dynamic environments**  
Consistently deliver high-impact data that drives strategic decision-making. Effective collaboration with internal teams and CRO partners.

## SKILLS

- Target discovery & Candidate selection
- Antibody engineering
- Assay development
- Cell-based assays
- Multi-colour FACS panel design
- Preclinical models
- Flowjo, FCS express, VivoQuant & Graphad
- Project leadership, CRO management
- Data integrity & analytical skills
- Attentiveness & Collaboration
- Efficient & Good communicator

## PUBLICATIONS

**GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions**  
*Immunotherapy Advances*, 2025

**Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell**  
*Science Advances*, 2022

**A dynamic COVID-19 immune signature includes associations with poor prognosis**  
*Nature Medicine*, 2020

## AWARDS

CRUK City of London PhD Fellowship  
Best poster award, CRUK City of London Center Symposium, 2021  
Exchange scholarship at the University of Melbourne, 2015-2016